HK1203837A1 - Immunogenic hpv l2-containing vlps and related compositions and methods - Google Patents

Immunogenic hpv l2-containing vlps and related compositions and methods Download PDF

Info

Publication number
HK1203837A1
HK1203837A1 HK15104584.7A HK15104584A HK1203837A1 HK 1203837 A1 HK1203837 A1 HK 1203837A1 HK 15104584 A HK15104584 A HK 15104584A HK 1203837 A1 HK1203837 A1 HK 1203837A1
Authority
HK
Hong Kong
Prior art keywords
hpv
peptide
composition
vlps
coat protein
Prior art date
Application number
HK15104584.7A
Other languages
English (en)
Chinese (zh)
Inventor
Bryce Chackerian
David Peabody
Ebenezer TUMBAN
Original Assignee
Stc.Unm公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stc.Unm公司 filed Critical Stc.Unm公司
Publication of HK1203837A1 publication Critical patent/HK1203837A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/18011—Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111—Leviviridae
    • C12N2795/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2795/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15104584.7A 2012-01-12 2013-01-10 Immunogenic hpv l2-containing vlps and related compositions and methods HK1203837A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261585839P 2012-01-12 2012-01-12
US61/585,839 2012-01-12
PCT/US2013/020960 WO2013106525A1 (en) 2012-01-12 2013-01-10 Immunogenic hpv l2-containing vlps and related compositions and methods

Publications (1)

Publication Number Publication Date
HK1203837A1 true HK1203837A1 (en) 2015-11-06

Family

ID=48781889

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104584.7A HK1203837A1 (en) 2012-01-12 2013-01-10 Immunogenic hpv l2-containing vlps and related compositions and methods

Country Status (8)

Country Link
EP (1) EP2802349B1 (enExample)
JP (1) JP6185932B2 (enExample)
CN (1) CN104159606A (enExample)
AU (1) AU2013207962B2 (enExample)
BR (1) BR112014017242A8 (enExample)
CA (1) CA2861021A1 (enExample)
HK (1) HK1203837A1 (enExample)
WO (1) WO2013106525A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549976B1 (en) 2012-11-16 2017-01-24 Stc.Unm Affinity selection of Nipah and Hendra virus-related vaccine candidates from a complex random peptide library displayed on bacteriophage virus-like particles
WO2014152211A1 (en) 2013-03-14 2014-09-25 Moderna Therapeutics, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
EP3041934A1 (en) 2013-09-03 2016-07-13 Moderna Therapeutics, Inc. Chimeric polynucleotides
US9943580B2 (en) 2013-09-12 2018-04-17 Stc.Unm Malaria vaccine
EA201690675A1 (ru) 2013-10-03 2016-08-31 Модерна Терапьютикс, Инк. Полинуклеотиды, кодирующие рецептор липопротеинов низкой плотности
WO2017136400A1 (en) * 2016-02-02 2017-08-10 Stc. Unm Vlp-based vaccines for targeting staphylococcus aureus secreted virulence factors
WO2017194903A2 (fr) 2016-05-13 2017-11-16 Vectalys Particule virale pour le transfert d'arns, notamment dans les cellules impliquées dans la réponse immune
WO2018213731A1 (en) 2017-05-18 2018-11-22 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (il12) polypeptides and uses thereof
WO2019063841A1 (en) * 2017-09-29 2019-04-04 Deutsches Krebsforschungszentrum VACCINE AGAINST SKIN PAPILLOMAVIRUS

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9113809D0 (en) * 1991-06-26 1991-08-14 Cancer Res Campaign Tech Papillomavirus l2 protein
GB9420146D0 (en) * 1994-10-06 1994-11-23 Cancer Res Campaign Tech Papillomavirus vaccine
US7320793B2 (en) * 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
US20090028886A1 (en) * 2004-08-04 2009-01-29 Cytos Biotechnology Ag Carrier conjugates of gnrh-peptides
US9533057B2 (en) * 2010-02-09 2017-01-03 Stc.Unm Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods

Also Published As

Publication number Publication date
AU2013207962A1 (en) 2014-08-07
CA2861021A1 (en) 2013-07-18
EP2802349A1 (en) 2014-11-19
JP6185932B2 (ja) 2017-08-23
AU2013207962B2 (en) 2017-07-20
WO2013106525A1 (en) 2013-07-18
BR112014017242A8 (pt) 2017-07-04
EP2802349B1 (en) 2017-12-06
BR112014017242A2 (pt) 2017-06-13
JP2015504897A (ja) 2015-02-16
EP2802349A4 (en) 2015-08-26
CN104159606A (zh) 2014-11-19

Similar Documents

Publication Publication Date Title
AU2013207962B2 (en) Immunogenic HPV L2-containing VLPs and related compositions and methods
AU2021232660B2 (en) HPV vaccines
TWI623618B (zh) Ｈｂｖ聚合酶突變體
CN113666990B (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
CN1462309A (zh) 经过密码子最优化的乳头状瘤病毒序列
SG177269A1 (en) Novel human papillomavirus (hpv) protein constructs and their use in the prevention of hpv disease
US9884107B2 (en) Immunogenic respiratory syncytial virus glycoprotein-containing VLPs and related compositions, constructs, and therapeutic methods
CN114213548B (zh) 同时诱导抗多种病毒的免疫应答的方法
Massa et al. Antitumor activity of DNA vaccines based on the human papillomavirus-16 E7 protein genetically fused to a plant virus coat protein
US20170096456A1 (en) Immunogenic hpv l2-containing vlps and related compositions, constructs, and therapeutic methods
US9717783B2 (en) Immunogenic HPV L2-containing VLPs and related compositions, constructs, and therapeutic methods
US8778351B2 (en) Combined human papillomavirus VLP/gene delivery system and use thereof as a vaccine for prophylaxis and immunotherapy of infectious diseases and tumors
WO2016026401A1 (zh) 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
CN101115766B (zh) 用于抗人乳头瘤病毒型16的salmonella疫苗菌株的密码子经优化的hpv16l1
CN103667319A (zh) 抗人乳头瘤病毒的三价疫苗及其制法和用途
Tornesello et al. Virus‑like particles as preventive and therapeutic cancer vac‑cines. Vaccines. 2022; 10: 227
JP6916115B2 (ja) ＨＰＶＬ２ペプチド／ＨＢｓキメラタンパク質を有効成分とするＨＰＶ感染症用ワクチン
CN119040348A (zh) 一种表达疟疾抗原的感染性克隆及其应用
Tyler Development of HPV next-generation virus-like particle vaccines that are cross-protective
CA2597865A1 (en) Compositions for therapeutic treatment of hpv related conditions and diseases